Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
01
04
2021
accepted:
28
08
2021
pubmed:
17
9
2021
medline:
15
9
2022
entrez:
16
9
2021
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, suppurative condition of the pilosebaceous unit. Patients suffering from HS demonstrate a molecular profile in keeping with a state of systemic inflammation and are often found to fit the criteria for a diagnosis of metabolic syndrome (MetS). In this paper, we review the literature with regards to established data on the prevalence of MetS in HS patients and revise the odds ratio of comorbid disease. Furthermore, we attempt to draw parallels between inflammatory pathways in HS and MetS and evaluate how convergences may explain the risk of comorbid disease, necessitating the need for multidisciplinary care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1186Informations de copyright
© 2021 the International Society of Dermatology.
Références
Frew JW. Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence. JAAD Int 2020; 1: 62-72.
Frew JW, Lowes MA, Goldfarb N, et al. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatol 2021; 157: 449-455.
Nguyen TV, Damiani G, Orenstein LAV, et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021; 35: 50-61.
Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017; 176: 1588-1598.
Vossen A, van Straalen KR, Swagemakers S, et al. A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significance. J Eur Acad Dermatol Venereol 2020; 34: 2353-2361.
Mintoff D, Pace NP, Bauer P, et al. A novel c.671_682del NCSTN variant in a family with Hidradenitis Suppurativa: a pilot study. Clin Exp Dermatol 2021. https://doi.org/10.1111/ced.14677. Online ahead of print.
Rodríguez-Zuñiga MJM, García-Perdomo HA, Ortega-Loayza AG. Association between hidradenitis suppurativa and metabolic syndrome: a systematic review and meta-analysis. Actas Dermosifiliogr 2019; 110: 279-288.
Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 2015; 73: S27-S35.
Bui T-L, Silva-Hirschberg C, Torres J, et al. Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 78: 395-402.
Garg A, Birabaharan M, Strunk A. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. J Am Acad Dermatol 2018; 79: 71-76.
Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clin Exp Dermatol 2019; 44: e126-e132.
Jørgensen A-HR, Aarestrup J, Baker JL, et al. Association of birth weight, childhood body mass index, and height with risk of hidradenitis suppurativa. JAMA Dermatol 2020; 156: 746-753.
Özkur E, Erdem Y, Altunay İK, et al. Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study. An Bras Dermatol 2020; 95: 708-713.
Akdogan N, Alli N, Uysal PI, et al. Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study. Arch Dermatol Res 2018; 310: 785-793.
González-Villanueva I, DeGracia C, Planells M, et al. Hidradenitis suppurativa is associated with non-alcoholic fatty liver disease: a cross-sectional study. Acta Derm Venereol 2020; 100: adv00239.
Damiani G, Leone S, Fajgenbaum K, et al. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: a multi-center retrospective analysis. World J Hepatol 2019; 11: 391-401.
Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 2015; 173: 464-470.
Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 2015; 173: 1142-1155.
Wertenteil S, Strunk A, Garg A. Association of low socioeconomic status with hidradenitis suppurativa in the United States. JAMA Dermatol 2018; 154: 1086-1088.
Sachdeva M, Shah M, Alavi A. Race-specific prevalence of hidradenitis suppurativa. J Cutan Med Surg 2021; 25: 177-187.
Moore JX. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017 [cited 2021 Feb 16]; 14. Available from: https://www.cdc.gov/pcd/issues/2017/16_0287.htm
Kjaersgaard Andersen R, Jørgensen IF, Reguant R, et al. Disease trajectories for hidradenitis suppurativa in the Danish population. JAMA Dermatol 2020; 156: 780-786.
Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014; 171: 819-824.
Sivanand A, Gulliver WP, Josan CK, et al. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J Cutan Med Surg 2020; 24: 64-72.
Miller IM, Rytgaard H, Mogensen UB, et al. Body composition and basal metabolic rate in Hidradenitis Suppurativa: a Danish population-based and hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2016; 30: 980-988.
Romaní J, Agut-Busquet E, Corbacho M, et al. Body fat composition in hidradenitis suppurativa: a hospital-based cross-sectional study. Int J Dermatol 2017; 56: e62-e63.
González-López MA, Hernández JL, Lacalle M, et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol 2016; 75: 329-335.
Vossen ARJV, van der Zee HH, Onderdijk AJ, et al. Hidradenitis suppurativa is not associated with the metabolic syndrome based on body type: a cross-sectional study. J Dermatol 2017; 44: 154-159.
Hernández JL, Baldeón C, López-Sundh AE, et al. Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study. Lipids Health Dis 2020; 19: 200.
Loo CH, Tan WC, Tang JJ, et al. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: a multicenter study. Int J Dermatol 2018; 57: 1454-1463.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
González-López MA, Vilanova I, Ocejo-Viñals G, et al. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Arch Dermatol Res 2020; 312: 595-600.
Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2013; 36: 166-175.
Festa A, D'Agostino R, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-294.
Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
Krogh-Madsen R, Plomgaard P, Møller K, et al. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 2006; 291: E108-E114.
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-86.
Cantley J. The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. Mamm Genome 2014; 25: 442-454.
Bluher M. Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab 2014; 3: 230-240.
Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36: 461-470.
Nov O, Shapiro H, Ovadia H, et al. Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS One 2013; 8: e53626.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
Søndergaard L. Homology between the mammalian liver and the Drosophila fat body. Trends Genet 1993; 9: 193.
Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity 2015; 23: 512-518.
Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
Miranda K, Yang X, Bam M, et al. MicroRNA-30 modulates metabolic inflammation by regulating Notch signaling in adipose tissue macrophages. Int J Obes 2018; 42: 1140-1150.
Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 141-150.
Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246.
Lanthier N, Molendi-Coste O, Horsmans Y, et al. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298: G107-G116.
Apostolopoulos V, de Courten MPJ, Stojanovska L, et al. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2016; 60: 43-57.
Song MJ, Kim KH, Yoon JM, et al. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006; 346: 739-745.
Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
Saberi M, Woods N-B, de Luca C, et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009; 10: 419-429.
Lee Y, Kim J-W, Osborne O, et al. Increased adipocyte O2 consumption triggers HIF-1α causing inflammation and insulin resistance in obesity. Cell 2014; 157: 1339-1352.
Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev 2013; 93: 1-21.
Khan T, Muise ES, Iyengar P, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009; 29: 1575-1591.
Jais A, Brüning JC. Hypothalamic inflammation in obesity and metabolic disease. J Clin Invest 2017; 3: 24-32.
Tanti J-F, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009; 9: 753-762.
Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296: E581-591.
Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010 [cited 2020 Nov 29]; 2010: 1-10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913796/
Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48: 1905-1914.
Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-209.
Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
Frederich RC, Hamann A, Anderson S, et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311-1314.
Yu D, Yu Z, Sun QI, et al. Effects of body fat on the associations of high-molecular-weight adiponectin, leptin and soluble leptin receptor with metabolic syndrome in Chinese. PLoS One 2011 [cited 2020 Nov 18]; 6: e16818. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039650/
Franks PW, Brage S, Luan J, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-1484.
Li W-C, Hsiao K-Y, Chen I-C, et al. Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol 2011; 10: 36.
García-Jiménez S, Bernal Fernández G, Martínez Salazar MF, et al. Serum leptin is associated with metabolic syndrome in obese Mexican subjects. J Clin Lab Anal 2014; 29: 5-9.
Tian Z, Sun R, Wei H, et al. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002; 298: 297-302.
Caldefie-Chezet F, Poulin A, Tridon A, et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 2001; 69: 414-418.
Santos-Alvarez J, Goberna R, Sánchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999; 194: 6-11.
Suzukawa M, Nagase H, Ogahara I, et al. Leptin enhances survival and induces migration, degranulation, and cytokine synthesis of human basophils. J Immunol 2011; 186: 5254-5260.
Kato H, Ueki S, Kamada R, et al. Leptin has a priming effect on eotaxin-induced human eosinophil chemotaxis. Int Arch Allergy Immunol 2011; 155: 335-344.
Agrawal S, Gollapudi S, Su H, et al. Leptin activates human B cells to secrete TNF-α, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. J Clin Immunol 2011; 31: 472-478.
Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901.
Vaisse C, Halaas JL, Horvath CM, et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996; 14: 95-97.
Bjørbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-4755.
Donato J Jr, Frazão R, Elias CF. The PI3K signaling pathway mediates the biological effects of leptin. Arq Bras Endocrinol Metabol 2010; 54: 591-602.
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
Li HS, Watowich SS. Innate immune regulation by STAT-mediated transcriptional mechanisms. Immunol Rev 2014; 261: 84-101.
Ramalingam P, Poulos MG, Lazzari E, et al. Chronic activation of endothelial MAPK disrupts hematopoiesis via NFKB dependent inflammatory stress reversible by SCGF. Nat Commun 2020 [cited 2020 Nov 18]; 11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997369/
Dayakar A, Chandrasekaran S, Veronica J, et al. Leptin regulates Granzyme-A, PD-1 and CTLA-4 expression in T cell to control visceral leishmaniasis in BALB/c Mice. Sci Rep 2017; 7: 14664.
Zhao Y, Sun R, You L, et al. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 2003; 300: 247-252.
Yang W-H, Liu S-C, Tsai C-H, et al. Leptin Induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts. PLoS One 2013 [cited 2020 Nov 18]; 8: e75551. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785513/
Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001; 167: 4593-4599.
Ziegler JF, Böttcher C, Letizia M, et al. Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn's disease. Nat Commun 2019 [cited 2020 Nov 18]; 10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904732/
Lee S-M, Choi H-J, Oh C-H, et al. Leptin increases TNF-α expression and production through phospholipase D1 in Raw 264.7 cells. PLoS One 2014; 9: e102373.
Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093-1103.
Bruno A, Conus S, Schmid I, et al. Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. J Immunol 2005; 174: 8090-8096.
Conus S, Bruno A, Simon H-U. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 2005; 116: 1228-1234.
Mattioli B, Straface E, Quaranta MG, et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174: 6820-6828.
Oswald J, Büttner M, Jasinski-Bergner S, et al. Leptin affects filopodia and cofilin in NK-92 cells in a dose- and time-dependent manner. Eur J Histochem 2018 [cited 2020 Nov 18]; 62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806502/
Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65.
Voloshyna I, Mounessa J, Carsons SE, et al. Effect of inhibition of interleukin-12/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophages. Clin Exp Dermatol 2016; 41: 308-311.
Singh UP, Singh NP, Guan H, et al. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol 2014; 33: 23-33.
Tian G, Liang J-N, Wang Z-Y, et al. Emerging role of leptin in rheumatoid arthritis. Clin Exp Immunol 2014; 177: 557-570.
Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
Zahary MN, Harun NS, Yahaya R, et al. Serum adiponectin and resistin: correlation with metabolic syndrome and its associated criteria among temiar subtribe in Malaysia. Diabetes Metab Syndr 2019; 13: 2015-2019.
Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol 2018; 18: 1031-1063.
Frühbeck G, Catalán V, Rodríguez A, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep 2017; 26: 6619.
Ohashi K, Shibata R, Murohara T, et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014; 25: 348-355.
Luo Y, Liu M. Adiponectin: a versatile player of innate immunity. J Mol Cell Biol 2016; 8: 120-128.
Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732.
Tilija Pun N, Park P-H. Role of p62 in the suppression of inflammatory cytokine production by adiponectin in macrophages: Involvement of autophagy and p21/Nrf2 axis. Sci Rep 2017 [cited 2020 Nov 19]; 7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428427/
Into T, Inomata M, Niida S, et al. Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by Sequestosome 1 and Histone Deacetylase 6. J Biol Chem 2010; 285: 35759-35769.
Upadhyaya S, Kadamkode V, Mahammed R, et al. Adiponectin and IL-6. Adipocyte 2014; 3: 39-45.
Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674.
Tsuji S, Uehori J, Matsumoto M, et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001; 276: 23456-23463.
Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metabol Syndr 2012; 4: 37.
de Souza Batista CM, Yang R-Z, Lee M-J, et al. omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661.
Alizadeh S, Mirzaei K, Mohammadi C, et al. Circulating omentin-1 might be associated with metabolic health status in different phenotypes of body size. Arch Endocrinol Metab 2017; 61: 567-574.
Rothermel J, Lass N, Barth A, et al. Link between omentin-1, obesity and insulin resistance in children: findings from a longitudinal intervention study. Pediatr Obes 2020; 15: e12605.
Pan X, Kaminga AC, Wen SW, et al. Omentin-1 in diabetes mellitus: a systematic review and meta-analysis. PLoS One 2019; 14: e0226292.
Zhang Q, Zhu L, Zheng M, et al. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults. Ann Endocrinol (Paris) 2014; 75: 171-175.
Zhou J-Y, Chan L, Zhou S-W. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014; 12: 136-143.
Zhong X, Li X, Liu F, et al. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun 2012; 425: 401-406.
Sumagin R, Lomakina E, Sarelius IH. Leukocyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol 2008; 295: H969-H977.
Maruyama S, Shibata R, Kikuchi R, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012; 287: 408-417.
Franik G, Sadlocha M, Madej P, et al. Circulating omentin-1 levels and inflammation in polycystic ovary syndrome. Ginekol Pol 2020; 91: 308-312.
Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Comm 2003; 300: 472-476.
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
Onalan E, Yakar B, Barım AO, et al. Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome. Endokrynol Pol 2020; 71: 319-324.
Ibrahim SM, Bastawy AA. The relevance of single-nucleotide polymorphism +62 G>A to the expression of resistin gene affecting serum resistin levels in metabolic syndrome in the Egyptian population. Curr Pharm Biotechnol 2020; 21: 626-634.
Makni E, Moalla W, Benezzeddine-Boussaidi L, et al. Correlation of resistin with inflammatory and cardiometabolic markers in obese adolescents with and without metabolic syndrome. OFA 2013; 6: 393-404.
Kougias P, Chai H, Lin PH, et al. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005; 41: 691-698.
Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-419.
Lund MAV, Thostrup AH, Frithioff-Bøjsøe C, et al. Low-grade inflammation independently associates with cardiometabolic risk in children with overweight/obesity. Nutr Metab Cardiovasc Dis 2020; 28: 1544-1553.
Christou KA, Christou GA, Karamoutsios A, et al. The regulation of serum resistin levels in metabolically healthy and unhealthy obese individuals. Hormones 2020; 19: 523-529.
Wen F, Xia Q, Zhang H, et al. Resistin activates p65 pathway and reduces glycogen content through keratin 8. Int J Endocrinol 2020; 2020: 9767926.
Cheleschi F, Gallo Q, Barbarino H, et al. MicroRNA mediate visfatin and resistin induction of oxidative stress in human osteoarthritic synovial fibroblasts via NF-κB pathway. Int J Mol Sci 2019; 20: 5200.
Lee S, Lee H-C, Kwon Y-W, et al. Adenylyl Cyclase-Associated Protein 1(CAP1) is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014; 19: 484-497.
Deshmukh SK, Srivastava SK, Bhardwaj A, et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget 2015; 6: 11231-11241.
Robertson SA, Rae CJ, Graham A. Induction of angiogenesis by murine resistin: putative role of PI3-kinase and NO-dependent pathways. Regul Pept 2009; 152: 41-47.
Kushiyama A, Shojima N, Ogihara T, et al. Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem 2005; 280: 42016-42025.
Hu W-L, Qian S-B, Li J-J. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine 2007; 40: 201-206.
de Luis DA. Resistin levels and inflammatory markers in patients with morbid obesity. Nutr Hosp 2010; 630-634.
Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. F1000Res 2018; 7: 1930.
Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J Leukoc Biol 2005; 78: 805-818.
Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis. JAMA Dermatol 2018; 1: 592-595.
Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065.
Haapasalo A, Kovacs DM. The many substrates of presenilin/γ-secretase. J Alzheimers Dis 2011; 25: 3-28.
Hessam S, Gambichler T, Skrygan M, et al. Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2021 [cited 2020 Dec 7]; 35: 203-210. Available from: https://onlinelibrary.wiley.com/doi/abs/ https://doi.org/10.1111/jdv.16962
Pajvani UB, Qiang L, Kangsamaksin T, et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013; 19: 1054-1060.
Bi P, Kuang S. Notch signaling as a novel regulator of metabolism. Trends Endocrinol Metab 2015; 26: 248-255.
Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol 2017; 18: 555-562.
Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013; 149: 762-764.
Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 2011; 8: 135-145.
Langan EA, Recke A, Bokor-Billmann T, et al. The role of the cutaneous microbiome in hidradenitis suppurativa-light at the end of the microbiological tunnel. Int J Mol Sci 2020 [cited 2020 Dec 7]; 21: 1205. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072827/
Guet-Revillet H, Jais J-P, Ungeheuer M-N, et al. The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis 2017; 65: 282-291.
Kim CH. Immune regulation by microbiome metabolites. Immunology 2018; 154: 220-229.
Yang G, Chen S, Deng B, et al. Implication of G protein-coupled receptor 43 in intestinal inflammation: a mini-review. Front Immunol 2018 [cited 2020 Dec 7]; 9. Available from: https://doi.org/10.3389/fimmu.2018.01434
Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet 2019; 51: 600-605.
Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012; 23: 351-363.
Malara A, Hughes R, Jennings L, et al. Adipokines are dysregulated in patients with hidradenitis suppurativa. Br J Dermatol 2018; 178: 792-793.
Abella V, Scotece M, Conde J, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol 2017; 13: 100-109.
Xu H, Xiao X, He Y, et al. Increased serum interleukin-6 levels in patients with hidradenitis suppurativa. Postepy Dermatol Alergol 2017; 34: 82-84.
Stelzer I, Zelzer S, Raggam RB, et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl Res 2012; 159: 118-124.
Jiménez-Gallo D, de la Varga-Martínez R, Ossorio-García L, et al. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017 [cited 2020 Nov 12]. ; 2017: 1-8. Available from: https://www.hindawi.com/journals/mi/2017/2450401/
González-Manso A, Agut-Busquet E, Romaní J, et al. Hidradenitis suppurativa: proposal of classification in two endotypes with two-step cluster analysis. Dermatology 2021; 237: 365-371.
Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009; 133: 157-170.
van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-1298.
Tsiotra PC, Boutati E, Dimitriadis G, et al. High insulin and leptin increase resistin and inflammatory cytokine production from human mononuclear cells. BioMed Res Int 2013 [cited 2020 Nov 10]; 2013: 1-10. Available from: https://www.hindawi.com/journals/bmri/2013/487081/
Dopytalska K, Baranowska-Bik A, Roszkiewicz M, et al. The role of leptin in selected skin diseases. Lipids Health Dis 2020; 19: 215.
Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007; 39: 250-255.
Chang Y-H, Chang D-M, Lin K-C, et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527.
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
Macklis PC, Tyler K, Kaffenberger J, et al. Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. Arch Dermatol Res 2021. https://doi.org/10.1007/s00403-021-02233-y. Online ahead of print.
Damiani G, Mahroum N, Pigatto PDM, et al. The safety and impact of a model of intermittent, time-restricted circadian fasting (“Ramadan Fasting”) on hidradenitis suppurativa: insights from a multicenter, observational, cross-over, pilot, exploratory study. Nutrients 2019; 11: 1781.
Jennings L, Hambly R, Hughes R, et al. Metformin use in hidradenitis suppurativa. J Dermatolog Treat 2020; 31: 261-263.
Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-616.
Frew JW, Jiang CS, Singh N, et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol 2020; 82: 1150-1157.
Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa. DRM 2020; 236: 25-30.
Sánchez Martínez EM, Murray G, Alfageme Roldán F, et al. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicenter study. Br J Dermatol 2021. https://doi.org/10.1111/bjd.20525. Online ahead of print.
Ghias MH, Johnston AD, Kutner AJ, et al. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol 2020; 82: 1094-1101.
Damiani G, Della Valle V, Iannone M, et al. Autoinflammatory Disease Damage Index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice. Ann Rheum Dis 2017; 76: e25.
Durán-Vian C, Arias-Loste MT, Hernández JL, et al. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol 2019; 33: 2131-2136.
Chiricozzi A, Giovanardi G, Caposiena Caro DR, et al. Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study. G Ital Dermatol Venereol 2020; 155: 335-340.
Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150: 1273-1280.
Gold DA, Reeder VJ, Mahan MG, et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014; 70: 699-703.
Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012; 7: e31810.